Cornerstone Capital Management Holdings’s Enanta Pharmaceuticals ENTA Stock Holding History

Cornerstone Capital Management Holdings’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-25,400	Closed	-$675K	–	1351
2016 Q3	$675K	Buy	25,400 +5,200	+26%	+$121K	0.01%	1021
2016 Q2	$446K	Sell	20,200 -62,651	-76%	-$1.64M	﹤0.01%	1059
2016 Q1	$2.43M	Buy	82,851 +50,000	+152%	+$1.39M	0.02%	674
2015 Q4	$1.08M	Buy	32,851 +17,551	+115%	+$572K	0.01%	877
2015 Q3	$553K	Sell	15,300 -16,300	-52%	-$700K	0.01%	985
2015 Q2	$1.42M	Buy	31,600 +27,900	+754%	+$1.09M	0.01%	813
2015 Q1	$113K	Buy	+3,700	New	+$144K	﹤0.01%	1255
2013 Q4	–	Sell	-5,200	Closed	-$119K	–	1270
2013 Q3	$119K	Buy	+5,200	New	+$99.4K	﹤0.01%	1108

Other funds holding ENTA

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Cornerstone Capital Management Holdings's ENTA Position: Q4 2016 in Review

Cornerstone Capital Management Holdings sold out of Enanta Pharmaceuticals (ENTA) in Q4 2016, closing a stake of 25,400 shares — an estimated $675K sold.

Cornerstone Capital Management Holdings first reported a position in ENTA in Q3 2013 and held it in 8 quarters. The position peaked at $2.43M in Q1 2016. 149 funds tracked by Wall St. Rank hold ENTA as of Q4 2016.

Cornerstone Capital Management Holdings reported no remaining Enanta Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Cornerstone Capital Management Holdings sold 25,400 Enanta Pharmaceuticals shares in Q4 2016, an estimated $675K.
Cornerstone Capital Management Holdings first reported a position in Enanta Pharmaceuticals in Q3 2013 and held it in 8 quarters.
Cornerstone Capital Management Holdings's Enanta Pharmaceuticals position peaked at $2.43M in Q1 2016.
149 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2016.

Based on Cornerstone Capital Management Holdings's 13F filing for Q4 2016, filed 14 Feb 2017.